Evidence map›Paper›PMID 18649149›Full record

ArticleMolecular biotechnology2009

Yeast-secreted recombinant extracellular domain of human CD105 antigen is able to bind TGF-beta type II receptor in vitro.

Giancarlo Basile, Manuela Peticca, Patrizia Cusano, Sergio Catello

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biotechnology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Giancarlo BasileTecnogen S.p.A., Piana di Monte Verna, Caserta, Italy. gbasile@exelgen.com
Manuela Peticca
Patrizia Cusano
Sergio Catello

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human CD105 antigen, a type I integral membrane glycoprotein, is expressed as homodimer and oligomer by human endothelial cells, and forms a heteromeric association with TGF-beta signaling receptors I and II. Several mutations of CD105 antigen gene are involved in a vascular disorder known as hereditary hemorrhagic telangiectasia type 1. The proposed mechanism by which CD105 is involved in said disorder is haploinsufficiency. We report expression and characterization of human CD105 antigen extracellular domain in yeast Saccharomyces cerevisiae. Different strategies to influence the release of heterologous proteins in the medium, such as alteration of cell wall integrity or coexpression of protein disulfide isomerase, were addressed. Purified extracellular domain of human CD105 antigen retains capacity to bind human TGF-beta receptor II in vitro.

Indexed as

Antigens, CDCloning, MolecularEndoglinHL-60 CellsHumansProtein Disulfide-IsomerasesProtein Serine-Threonine KinasesReceptors, Cell SurfaceReceptors, Transforming Growth Factor betaReceptor, Transforming Growth Factor-beta Type IIRecombinant ProteinsSaccharomyces cerevisiaeAntigens, CDEndoglinENG protein, humanProtein Disulfide-IsomerasesProtein Serine-Threonine KinasesReceptors, Cell SurfaceReceptors, Transforming Growth Factor betaReceptor, Transforming Growth Factor-beta Type IIRecombinant Proteins

Identifiers

PMID18649149

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.